Fish skin gelatin hydrolysates as dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 stimulators improve glycaemic control in diabetic rats: A comparison between warm- and cold-water fish

Journal of Functional Foods

Volumn 19, Issue , 2015, Pages 330-340

  Wang, Tzu Yuan ^a   Hsieh, Cheng Hong ^b   Hung, Chuan Chuan ^b,c   Jao, Chia Ling ^d   Chen, Meng Chun ^c   Hsu, Kuo Chiang ^b,c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d TUNG FANG DESIGN UNIVERSITY   (Taiwan)

Author keywords

Aprotinin; Cold water fish; DPP IV; Gelatin; GLP 1; Nicotinamide; Proline; Streptozotocin; Warm water fish

Indexed keywords

EID: 84946409694     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2015.09.037     Document Type: Article

References (50)

1. Aart V.A., Catharina M.J., Zeeland-Wolbers V., Maria L.A., Gilst V., Hendrikus W., Nelissen B.J.H., Maria J.W.P. Egg protein hydrolysates 2009, WO 2009/128713.
2. Ahren B. GLP-1 and extra-islet effects. Hormone and Metabolic Research 2004, 36:842-845.
3. Ben-Avraham S., Harman-Boehm I., Schwarzfuchs D., Shai I. Dietary strategies for patients with type 2 diabetes in the era of multi-approaches: Review and results from the dietary intervention randomized controlled trial (DIRECT). Diabetes Research and Clinical Practice 2009, 86:41-48.
4. Chen Q., Reimer R.A. Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition (Burbank, Los Angeles County, Calif.) 2009, 25:340-349.
5. Cheow C.S., Norizah M.S., Kyaw Z.Y., Howell N.K. Preparation and characterisation of gelatins from the skins of sin croaker (Johnius dussumieri) and shortfin scad (Decapterus macrosoma). Food Chemistry 2007, 101:386-391.
6. Cordier-Bussat M., Bernard C., Levenez F., Klages N., Laser-Ritz B., Philippe J., Chayvialle J.A., Cuber J.C. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 1998, 47:1038-1045.
7. De León D.D., Crutchlow M.F., Ham J.Y.N., Stoffers A.S. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. The International Journal of Biochemistry & Cell Biology 2006, 38:845-859.
8. De Meester I., Lambeir A.M., Proost P., Scharpé S. Dipeptidyl peptidase IV substrates. Advances in Experimental Medicine and Biology 2003, 524:3-13.
9. Deacon C.F., Holst J.J. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. The International Journal of Biochemistry & Cell Biology 2006, 38:831-844.
10. Deacon C.F., Nauck M.A., Meier J., Hücking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetes subjects as revealed using a new assay for the intact peptide. The Journal of Clinical Endocrinology & Metabolism 2000, 85:3575-3581.
11. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
12. Do S.G., Park J.H., Nam H., Kim J.B., Lee J.Y., Oh Y.S., Suh J.G. Silk fibroin hydrolysate exerts an anti-diabetic effect by increasing pancreatic β cell mass in C57BL/KsJ-db/db mice. Journal of Veterinary Science 2012, 13:339-344.
13. Gaudel C., Nongonierma A.B., Maher S., Flynn S., Krause M., Murray B.A., Kelly P.M., Baird A.W., FitzGerald R.J., Newsholme P. A whey protein hydrolysate promotes insulinotropic activity in a clonal pancreatic beta-cell line and enhances glycemic function in ob/ob mice. Journal of Nutrition 2013, 143:1109-1114.
14. Gooben K., Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes, Obesity and Metabolism 2012, 14:1061-1072.
15. Hall W.L., Millward D.J., Long S.J., Morgan L.M. Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. British Journal of Nutrition 2003, 89:239-248.
16. Hansotia T., Drucker D.J. GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice. Regulatory Peptides 2005, 128:125-134.
17. Hira T., Mochida T., Miyashita K., Hara H. GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysates, in rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 2009, 297:G663-G671.
18. Hsieh C.H., Wang T.Y., Hung C.C., Chen M.C., Hsu K.C. Improvement of glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor. Food & Function 2015, 6:1887-1892.
19. Hsu K.C., Tung Y.S., Huang S.L., Jao C.L. Chapter 8: Dipeptidyl peptidase-IV inhibitory activity of peptides in porcine skin gelatin hydrolysates. Bioactive food peptides in health and disease 2013, Intech Prepress, Rijeka, Croatia. B. Hernández-Ledesma, C.C. Hsieh (Eds.).
20. Huang S.L., Hung C.C., Jao C.L., Tung Y.S., Hsu K.C. Porcine skin gelatin hydrolysate as a dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-induced diabetic rats. Journal of Functional Foods 2014, 11:235-242.
21. Huang S.L., Jao C.L., Ho K.P., Hsu K.C. Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides 2012, 35:114-121.
22. Karim A.A., Bhat R. Fish gelatin properties, challenges, and prospects as an alternative to mammalian gelatins. Food Hydrocolloids 2009, 23:563-567.
23. Kaspar H., Dettmer K., Gronwald W., Oefner P.J. Advances in amino acid analysis. Analytical and Bioanalytical Chemistry 2009, 393:445-452.
24. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
25. Kim S.J., Nian C., Doudet D.J., McIntosh C.H.S. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008, 57:1331-1339.
26. Kojima K., Ham T., Kato T. Rapid chromatographic purification of dipeptidyl peptidase IV in human submaxillary gland. Journal of Chromatography 1980, 189:233-240.
27. Krushner P., Gorrell M. DPP-4 inhibitors in type 2 diabetes: Importance of selective enzyme inhibition and implications for clinical use. Journal of Family Practice 2010, 59(2).
28. Lacroix I.M.E., Li-Chan E.C.Y. Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. Journal of Functional Foods 2012, 4:403-422.
29. Lacroix I.M.E., Li-Chan E.C.Y. Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins. Peptides 2014, 54:39-48.
30. Lambeir A.M., Durinx C., Scharpé S., De Meester I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions and clinical aspects of the enzyme DPP IV. Critical Reviews in Clinical Laboratory Science 2003, 40:209-294.
31. Li-Chan E.C.Y., Huang S.L., Jao C.L., Ho K.P., Hsu K.C. Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. Journal of Agricultural and Food Chemistry 2012, 60:973-978.
32. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Shiraki K., Hayakawa M., Shibasaki M. Antidiabetic effects of dipeptidyl peptidase-IV inhibitor and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism: Clinical and Experimental 2009, 58:379-386.
33. McIntosh C.H.S., Demuth H.U., Pospisilik J.A., Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents. Regulatory Peptides 2005, 128:159-165.
34. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, and peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 1993, 214:829-835.
35. Mitani H., Takimoto M., Hughes T.E., Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity. The Japanese Journal of Pharmacology 2002, 88:442-450.
36. Murugan P., Pari L. Antioxidant effect of tetrahydrocurcumin in streptozotocin-nicotinamide induced diabetic rats. Life Sciences 2006, 79:1720-1728.
37. Pieter B.J.W. Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use 2006, WO 2006/068480.
38. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.U., McIntosh C.H., Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52:741-750.
39. Power O., Nongonierma A.B., Jakeman P., FitzGerald R.J. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes. Proceedings of the Nutrition Society 2014, 73:34-46.
40. Reimer R.A. Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. Journal of Endocrinology 2006, 191:159-170.
41. Renukuntla J., Vadlapudi A.D., Patel A., Boddu S.H.S., Mitra A.K. Approaches for enhancing oral bioavailability of peptides and proteins. International Journal of Pharmaceutics 2013, 447:75-93.
42. Sangle G.V., Lauffer L.M., Grieco A., Trivedi S., Iakoubov R., Brubaker P.L. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology 2012, 153:564-573.
43. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 2013, 12:545-557.
44. Sebokova E., Christ A.D., Boehringer M., Mizrahi J. Dipeptidyl peptidase IV inhibitors: The next generation of new promising therapies for the management of type 2 diabetes. Current Topics in Medicinal Chemistry 2007, 7:547-555.
45. Silveira S.T., Martínez-Maqueda D., Recio I., Hernández-Ledesma B. Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin. Food Chemistry 2013, 141:1072-1077.
46. Tulipano G., Sibilia V., Caroli A.M., Cocchi D. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 2011, 32:835-838.
47. Uchida M., Ohshiba Y., Mogami O. Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin. Journal of Pharmacological Science 2011, 117:63-66.
48. Umezawa H., Aoyagi T., Ogawa K., Naganawa H., Hamada M., Takeuchi T. Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. The Journal of Antibiotics 1984, 37:422-425.
49. Vilsboll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes. Diabetologia 2004, 47:357-366.
50. World Health Organisation Diabetes programme, country and regional data Accessed 12.09.12. http://www.who.int/diabetes/facts/world_figures/en/.